Loading...
Market
Will Sangamo submit BLA for ST-920 by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Sangamo Therapeutics' official press releases or FDA announcements
Story
Sangamo Therapeutics Aligns with FDA for Accelerated Approval of ST-920 Gene Therapy for Fabry Disease by 2025
Oct 22, 2024, 12:12 PM
Sangamo Therapeutics announced that it has reached an agreement with the U.S. FDA on an Accelerated Approval pathway for its ST-920 gene therapy product candidate for the treatment of Fabry disease. This alignment is expected to accelerate the potential approval timeline by approximately three years, with a Biologics License Application (BLA) submission anticipated in the second half of 2025. The FDA's decision is a significant step forward for Sangamo's efforts in addressing this rare disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Up by more than 50% • 25%
Up by 0% to 50% • 25%
Down by 0% to 50% • 25%
Down by more than 50% • 25%
